BioTuesdays

Category - Developments

Regenicin
Developments

Regenicin gets orphan-drug status for NovaDerm

The FDA has granted orphan-drug status to Regenicin’s (OTC:RGIN) NovaDerm cultured skin substitute. In a statement, the company said it believes NovaDerm to be the only autologous cultured skin substitute prepared from...

August 30, 2016
StemCells
Developments

StemCells and Microbot Medical to merge

StemCells (NASDAQ:STEM) and closely-held Microbot Medical of Israel have entered into a definitive merger agreement, with plans to pursue the development of robotics-based medical devices for the treatment of...

August 16, 2016
IntelGenx Logo
Developments

IntelGenx sells Forfivo XL royalty

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has sold its royalty on future sales of Forfivo XL to SWK Holdings for $6-million. Forfivo XL (bupropion extended release) is the first 450-milligram bupropion hydrogen chloride tablet...

August 6, 2016
Cellect Biotechnology
Developments

Cellect completes NASDAQ IPO

Cellect Biotechnology (NASDAQ:APOP; TASE:CLBD) priced an initial public offering in the U.S. of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs. Each ADS, representing 20 ordinary...

August 3, 2016
oramed
Developments

Oramed gets additional milestone from HTIT

Oramed Pharmaceuticals (NASDAQ:ORMP) has received a milestone payment of $4-million from Hefei Tianhui Incubator of Technologies (HTIT) of China. The milestone is part of a license and investment agreement between...

August 2, 2016